SCHEMBL3665002

SCHEMBL3665002

Brc1cncc(-c2cc(NC3CC3)nc(-c3ccccn3)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR39 O43194 5/20 0.47
CSNK2A2 P19784 1/20 0.37
MERTK Q12866 7/20 0.37
TYRO3 Q06418 6/20 0.37
FLT3 P36888 5/20 0.37
GAS6 Q14393 5/20 0.37
CCNT1 O60563 1/20 0.36
CCR6 P51684 1/20 0.36
AXL P30530 2/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
EGFR P00533 1/20 0.36
BTK Q06187 1/20 0.36
MAPK14 Q16539 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664859 0.96 GPR39 (0.51) GPR39MERTKTYRO3FLT3GAS6
SCHEMBL3663909 0.96 GPR39 (0.54) GPR39MERTKTYRO3FLT3GAS6
SCHEMBL3661666 0.84 GPR39 (0.45) GPR39CSNK2A2MERTKTYRO3FLT3
SCHEMBL3662536 0.84 GPR39 (0.55) GPR39MERTKTYRO3FLT3GAS6
SCHEMBL3662671 0.83 EGFR (0.37) GPR39CCNT1PIM1PIM3PIM2
SCHEMBL4192009 0.82 GPR39 (0.43) GPR39MERTKTYRO3FLT3GAS6
SCHEMBL3663705 0.82 GPR39 (0.43) GPR39MERTKTYRO3FLT3GAS6
SCHEMBL3667875 0.81 GPR39 (0.37) GPR39
SCHEMBL3661769 0.81 KDM4E (0.37) GPR39
SCHEMBL3659080 0.81 CYP1A2 (0.45) GPR39FLT3MAPK14TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK GPR39 222/4885CSNK2A2 2761/4885MERTK 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.